HDAC9 and hematologic disorder: Notably, targeted epigenetic therapy has gained wide acceptance in both preclinical and clinical trials for hematologic malignancies, signifying promising applications for treating solid tumors (Cheng et al., 2019).The utilization of epigenetic drugs, including demethylating compounds and HDAC inhibitors, has exhibited the ability to reactivate tumor suppressor genes and essential cellular functional genes by specifically targeting abnormal chromatin regions (Jones and Baylin, 2007).